Search
forLearn
5 / 801 resultsResearch
5 / 143 resultsresearch Neurosteroids and epileptogenesis in the pilocarpine model: Evidence for a relationship between P450scc induction and length of the latent period
Neurosteroid production in the brain may delay seizure onset.
research Human Skin is a Steroidogenic Tissue: Steroidogenic Enzymes and Cofactors Are Expressed in Epidermis, Normal Sebocytes, and an Immortalized Sebocyte Cell Line (SEB-1)
Human skin can produce steroids from cholesterol.
research Palmitoylethanolamide Stimulation Induces Allopregnanolone Synthesis in C6 Cells and Primary Astrocytes: Involvement of Peroxisome-Proliferator Activated Receptor-α
PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.
research Neurosteroids and Epileptogenesis
Neurosteroids may help prevent seizures and slow epilepsy progression.
research SHORT-TERM DIABETES IN THE BRAIN: EFFECTS ON NEUROACTIVE STEROIDS, CHOLESTEROL HOMEOSTASIS, AND MITOCHONDRIAL FUNCTIONALITY
Short-term diabetes can cause changes in brain steroids, cholesterol balance, and mitochondrial function.
Community Join
5 / 1000+ resultscommunity Quit vaping/smoking = 80% less loss
Quitting vaping significantly reduced hair loss for a user who was a heavy vaper and also taking finasteride. Some participants suggest nicotine's vasoconstrictive properties may worsen hair loss, while others share personal anecdotes of hair improvement after quitting smoking or vaping.
community Is there a topical androgen receptor blocker so we don't have to fuck with the enzyme and destroy our allopregnanolone, but go and hit the end target straight?
The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.